Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Increased all-cause mortality in concomitant atopic dermatitis and asthma : A nationwide registry-based study. / Ali, Zarqa; Ulrik, Charlotte Suppli; Egeberg, Alexander; Thyssen, Jacob Pontoppidan; Francis Thomsen, Simon.
I: Clinical and Experimental Allergy, Bind 51, Nr. 9, 2021, s. 1207-1217.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Increased all-cause mortality in concomitant atopic dermatitis and asthma
T2 - A nationwide registry-based study
AU - Ali, Zarqa
AU - Ulrik, Charlotte Suppli
AU - Egeberg, Alexander
AU - Thyssen, Jacob Pontoppidan
AU - Francis Thomsen, Simon
PY - 2021
Y1 - 2021
N2 - Background Excess mortality has been reported for adults with atopic dermatitis (AD) and asthma. Objective To assess the mortality rate in adults with concomitant AD and asthma. Methods Adults with hospital-diagnosed AD were matched (1:4) with non-AD individuals from the background population. Results The study cohort comprised 8,095 adults with AD (of which 1,201 (14.8%) had concomitant asthma) and 32,380 reference individuals without AD from the background population (of which 878 (2.7%) had asthma). A total of 1,057, 330, 55 and 99 deaths were observed among subjects with neither AD nor asthma, AD only, asthma only, and subjects with concomitant AD and asthma, respectively. The mortality rate per 1,000 person-years was 4.75 (95% CI 4.47-5.05) for subjects with neither AD nor asthma, 7.17 (95% CI 5.92-10.05) for asthma only, 7.09 (95% CI 6.37-7.90) for AD only and 10.87 (95% CI 8.92-13.23) for concomitant AD and asthma. Risk for all-cause mortality was increased in subjects with concomitant AD and asthma compared to asthma only (HR 1.52, 95% CI 1.07-2.15) and neither AD nor asthma (HR 2.27, 95% CI 1.83-2.81) but not compared to subjects with AD only (HR 1.10, 95% CI 0.87-1.39). However, compared to AD only subjects with AD and asthma had increased risk of death due to pulmonary disease (HR 1.81, 95% CI 1.04-3.15). Conclusion Adults with AD, asthma or both conditions have increased risk of death, and further concomitant AD and asthma have increased risk of death compared with asthma alone.
AB - Background Excess mortality has been reported for adults with atopic dermatitis (AD) and asthma. Objective To assess the mortality rate in adults with concomitant AD and asthma. Methods Adults with hospital-diagnosed AD were matched (1:4) with non-AD individuals from the background population. Results The study cohort comprised 8,095 adults with AD (of which 1,201 (14.8%) had concomitant asthma) and 32,380 reference individuals without AD from the background population (of which 878 (2.7%) had asthma). A total of 1,057, 330, 55 and 99 deaths were observed among subjects with neither AD nor asthma, AD only, asthma only, and subjects with concomitant AD and asthma, respectively. The mortality rate per 1,000 person-years was 4.75 (95% CI 4.47-5.05) for subjects with neither AD nor asthma, 7.17 (95% CI 5.92-10.05) for asthma only, 7.09 (95% CI 6.37-7.90) for AD only and 10.87 (95% CI 8.92-13.23) for concomitant AD and asthma. Risk for all-cause mortality was increased in subjects with concomitant AD and asthma compared to asthma only (HR 1.52, 95% CI 1.07-2.15) and neither AD nor asthma (HR 2.27, 95% CI 1.83-2.81) but not compared to subjects with AD only (HR 1.10, 95% CI 0.87-1.39). However, compared to AD only subjects with AD and asthma had increased risk of death due to pulmonary disease (HR 1.81, 95% CI 1.04-3.15). Conclusion Adults with AD, asthma or both conditions have increased risk of death, and further concomitant AD and asthma have increased risk of death compared with asthma alone.
KW - asthma
KW - atopic dermatitis
KW - eczema
KW - mortality
KW - 1,075 OUTPATIENTS
KW - SEX-DIFFERENCES
KW - DISEASE
KW - POPULATION
KW - ADULTS
KW - RISK
U2 - 10.1111/cea.13978
DO - 10.1111/cea.13978
M3 - Journal article
C2 - 34191378
VL - 51
SP - 1207
EP - 1217
JO - Clinical Allergy
JF - Clinical Allergy
SN - 0954-7894
IS - 9
ER -
ID: 274429103